Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome

doi:10.4292/wjgpt.v17.i1.117071

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (123)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=71

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=42

Mar 5, 2026 (publication date) through Mar 5, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 117071
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.117071

Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome

Jyoti Pathania, Vanya Pathania

Jyoti Pathania, Department of Anesthesia, Rohilkhand Medical College, Bareilly 243006, Uttar Pradesh, India

Vanya Pathania, Department of Gynaecology and Obstretics, Maharishi Markandeshwar Medical College and Hospital, Solan 173229, Himāchal Pradesh, India

Author contributions: Pathania J wrote the initial manuscript; Pathania V collected all the literature; Pathania J wrote and edited the final draft. All authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Jyoti Pathania, Department of Anesthesia, Rohilkhand Medical College, Pilbhit bypass road, Bareilly 243006, Uttar Pradesh, India. pathaniajyoti7@gmail.com

Received: November 28, 2025
Revised: December 17, 2025
Accepted: January 26, 2026
Published online: March 5, 2026
Processing time: 75 Days and 22.6 Hours

Core Tip

Core Tip: Teduglutide (rDNA) is a Food and Drug Administration sanctioned medication for individuals with short bowel syndrome. The majority of short bowel syndrome patients receive parenteral support, and this medication enhances their chances of achieving parenteral independence to different extents. Daily subcutaneous injections are routinely prescribed, along with regular gastrointestinal colonoscopies/endoscopies to observe the enterocyte dysplasia present in certain individuals. The expensive nature of the treatment significantly discourages its regular use, leading the prescribing physician to adjust its dosage. Nonetheless, only a limited number of treatment-related side effects are seen, making it the sole pharmacological choice for these patients.